The full text of this issue is now available to our subscribers. If you are a subscriber please log in now. You may also buy this issue by clicking on the button below.
This month Life Science Compliance Update focuses on the importance of compliance culture. First, we examine the difference between what current CIA’s require in compliance programs versus what the Ethics and Compliance Initiative’s Blue Ribbon Panel suggests. Tracey Keele from KPMG then explores whether improving culture will address the pharmaceutical industry’s image problem. Other highlights this month include an article by Huron’s Chris Cobourn on the recently finalized rule on Average Medicaid Price (“AMP”) calculations, and Kaitlin Fallon does a comparison review of some of the global codes of practices and ethics governing life sciences commercial operations.
Do Gold-Standard CIAs Get Blue Ribbon Approval?
Calisha D. Myers, Esq., Staff Writer
A Prescription for Life Science’s Regulatory Woes
Tracey Keele, Partner, KPMG Risk Consulting
The Black Hole – AMP as Viewed from A Pharmaceutical Manufacturer’s Compliance Office
Chris Cobourn, Managing Director, Huron Life Sciences
One Code to Bind Them All – Doubtful
Kaitlin P. Fallon, Esq., Staff Writer for Life Science Compliance Update
A Different Mindset – Challenges of Working in China
Kaitlin Fallon, Esq., Staff Writer for Life Science Compliance Update
Be Careful What You Sign Up For – Implied Certification and the False Claims Act (FCA)
Robert N. Wilkey, Esq., Staff Writer for Life Science Compliance Update
Exploring Strange New Worlds – FDA’s 2016 Program Alignment and Strategic Priorities
Calisha D. Myers, Esq., Staff Writer – Life Science Compliance Update